meeting of board of director to considered and approved the following 1.audited financial results 2. Statement of deviation or variation 3. take note on resignation of Rajendra prasad (Non- ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Johnson Pharmacare's board, which met on May 27, 2026, approved audited financial results for Q4 and the full year ended March 31, 2026, and noted two director resignations. Both Mr. Rajendra Prasad (Non-Executive Director) and Mr. Umesh Kumar (Executive Director) stepped down effective April 17, 2026, citing personal reasons. The company reported a revenue of just Rs 158.10 lakhs for FY26 against a staggering loss before tax of Rs 5,573.39 lakhs, with total expenses ballooning to Rs 4,304.49 lakhs and exceptional items of Rs 1,427 lakhs. Total assets shrank sharply from Rs 5,792.59 lakhs to Rs 2,203.11 lakhs, while borrowings stood at Rs 2,140.19 lakhs. The auditor issued a qualified opinion flagging non-compliance with Ind AS, non-provision of interest on loans, investments exceeding Section 186 limits, a complex multi-layered group structure, missing audit trail in accounting software, and pending tax demands running into several lakhs across multiple assessment years.
This is a deeply negative filing for shareholders — a near wipe-out in earnings, a qualified audit report, and the exit of two directors (including a KMP-level Executive Director) point to serious financial and governance stress. Investors should treat the stock with high caution as the company appears to be in distress, with shrinking assets, rising borrowings, and unresolved compliance issues.